Identification of COVID-19 and Dengue Host Factor Interaction Networks Based on Integrative Bioinformatics Analyses.
Antiviral Agents
/ therapeutic use
COVID-19
/ pathology
Chemokine CCL2
/ metabolism
Coinfection
Computational Biology
/ methods
Dengue
/ drug therapy
Dengue Virus
/ drug effects
Dexamethasone
/ therapeutic use
Gene Expression Regulation
/ genetics
Genistein
/ therapeutic use
Humans
Intercellular Adhesion Molecule-1
/ metabolism
Lung
/ metabolism
Protein Interaction Maps
/ physiology
Resveratrol
/ therapeutic use
SARS-CoV-2
/ drug effects
Signal Transduction
COVID-19 Drug Treatment
COVID-19
bioinformatics analyses
co-infection
dengue
host factor interaction networks
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
05
2021
accepted:
06
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
The outbreak of Coronavirus disease 2019 (COVID-19) has become an international public health crisis, and the number of cases with dengue co-infection has raised concerns. Unfortunately, treatment options are currently limited or even unavailable. Thus, the aim of our study was to explore the underlying mechanisms and identify potential therapeutic targets for co-infection. To further understand the mechanisms underlying co-infection, we used a series of bioinformatics analyses to build host factor interaction networks and elucidate biological process and molecular function categories, pathway activity, tissue-specific enrichment, and potential therapeutic agents. We explored the pathologic mechanisms of COVID-19 and dengue co-infection, including predisposing genes, significant pathways, biological functions, and possible drugs for intervention. In total, 460 shared host factors were collected; among them, CCL4 and AhR targets were important. To further analyze biological functions, we created a protein-protein interaction (PPI) network and performed Molecular Complex Detection (MCODE) analysis. In addition, common signaling pathways were acquired, and the toll-like receptor and NOD-like receptor signaling pathways exerted a significant effect on the interaction. Upregulated genes were identified based on the activity score of dysregulated genes, such as IL-1, Hippo, and TNF-α. We also conducted tissue-specific enrichment analysis and found ICAM-1 and CCL2 to be highly expressed in the lung. Finally, candidate drugs were screened, including resveratrol, genistein, and dexamethasone. This study probes host factor interaction networks for COVID-19 and dengue and provides potential drugs for clinical practice. Although the findings need to be verified, they contribute to the treatment of co-infection and the management of respiratory disease.
Sections du résumé
Background
The outbreak of Coronavirus disease 2019 (COVID-19) has become an international public health crisis, and the number of cases with dengue co-infection has raised concerns. Unfortunately, treatment options are currently limited or even unavailable. Thus, the aim of our study was to explore the underlying mechanisms and identify potential therapeutic targets for co-infection.
Methods
To further understand the mechanisms underlying co-infection, we used a series of bioinformatics analyses to build host factor interaction networks and elucidate biological process and molecular function categories, pathway activity, tissue-specific enrichment, and potential therapeutic agents.
Results
We explored the pathologic mechanisms of COVID-19 and dengue co-infection, including predisposing genes, significant pathways, biological functions, and possible drugs for intervention. In total, 460 shared host factors were collected; among them, CCL4 and AhR targets were important. To further analyze biological functions, we created a protein-protein interaction (PPI) network and performed Molecular Complex Detection (MCODE) analysis. In addition, common signaling pathways were acquired, and the toll-like receptor and NOD-like receptor signaling pathways exerted a significant effect on the interaction. Upregulated genes were identified based on the activity score of dysregulated genes, such as IL-1, Hippo, and TNF-α. We also conducted tissue-specific enrichment analysis and found ICAM-1 and CCL2 to be highly expressed in the lung. Finally, candidate drugs were screened, including resveratrol, genistein, and dexamethasone.
Conclusions
This study probes host factor interaction networks for COVID-19 and dengue and provides potential drugs for clinical practice. Although the findings need to be verified, they contribute to the treatment of co-infection and the management of respiratory disease.
Identifiants
pubmed: 34394108
doi: 10.3389/fimmu.2021.707287
pmc: PMC8356054
doi:
Substances chimiques
Antiviral Agents
0
CCL2 protein, human
0
Chemokine CCL2
0
ICAM1 protein, human
0
Intercellular Adhesion Molecule-1
126547-89-5
Dexamethasone
7S5I7G3JQL
Genistein
DH2M523P0H
Resveratrol
Q369O8926L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
707287Informations de copyright
Copyright © 2021 Zheng, Wu, Liu, Yan, Wang, Wu, Liu, Jiang and Zhan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Virol. 2007 Jun;81(11):5518-26
pubmed: 17360740
J Med Virol. 2021 Jan;93(1):80-82
pubmed: 32510175
PLoS Negl Trop Dis. 2013 Jul 04;7(7):e2295
pubmed: 23861987
Travel Med Infect Dis. 2020 May - Jun;35:101659
pubmed: 32278756
Cells. 2020 Oct 29;9(11):
pubmed: 33138195
J Infect Dis. 2020 Aug 17;222(6):894-898
pubmed: 32582936
PLoS Pathog. 2019 Apr 22;15(4):e1007625
pubmed: 31009511
Rev Fac Cien Med Univ Nac Cordoba. 2020 Mar 31;77(1):52-54
pubmed: 32238260
Nature. 2021 Feb;590(7847):635-641
pubmed: 33429418
Crit Care. 2020 May 6;24(1):198
pubmed: 32375845
Front Immunol. 2020 Mar 10;11:352
pubmed: 32210961
Nucleic Acids Res. 2014 Jan;42(Database issue):D1075-82
pubmed: 24198245
J Med Virol. 2021 Jan;93(1):522-527
pubmed: 32558962
Emerg Infect Dis. 2021 Feb;27(2):348-351
pubmed: 33347804
J Virol. 2019 Oct 15;93(21):
pubmed: 31413130
BMC Syst Biol. 2014;8 Suppl 4:S11
pubmed: 25521941
Database (Oxford). 2010 Aug 05;2010:baq020
pubmed: 20689021
Nutrients. 2019 Apr 26;11(5):
pubmed: 31035454
Cell Microbiol. 2009 Apr;11(4):604-15
pubmed: 19134117
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
J Immunol. 2017 Jun 15;198(12):4764-4771
pubmed: 28507028
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Lancet. 2015 Jan 31;385(9966):453-65
pubmed: 25230594
Rev Med Virol. 2021 Mar;31(2):e2161
pubmed: 32946149
PLoS One. 2010 Jan 14;5(1):e8709
pubmed: 20090849
Cell Rep Med. 2020 Dec 26;2(1):100166
pubmed: 33521697
Sci Rep. 2017 Feb 20;7:42998
pubmed: 28216632
Acta Biochim Biophys Sin (Shanghai). 2017 Sep 1;49(9):848-850
pubmed: 28910974
Nucleic Acids Res. 2017 Jan 4;45(D1):D833-D839
pubmed: 27924018
Am J Physiol Endocrinol Metab. 2020 Jul 1;319(1):E105-E109
pubmed: 32459524
Nucleic Acids Res. 2019 Jan 8;47(D1):D948-D954
pubmed: 30247620
Sci Rep. 2020 Nov 16;10(1):19839
pubmed: 33199778
J Virol. 2016 Nov 28;90(24):11259-11278
pubmed: 27707928
Cell Host Microbe. 2014 Jul 9;16(1):115-27
pubmed: 24981333
Cell Death Dis. 2017 Dec 13;8(12):3215
pubmed: 29238080
IDCases. 2020 Aug 05;22:e00927
pubmed: 32802747
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Clin Infect Dis. 2020 Aug 14;:
pubmed: 32797228
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H18-24
pubmed: 20418481
Signal Transduct Target Ther. 2020 May 29;5(1):84
pubmed: 32467561
J Virol. 2008 Dec;82(24):12312-24
pubmed: 18842737
Physiol Behav. 1981 May;26(5):763-71
pubmed: 7267769
Am J Trop Med Hyg. 2001 Jul;65(1):70-5
pubmed: 11504411
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Nat Rev Rheumatol. 2010 Apr;6(4):232-41
pubmed: 20177398
PLoS Negl Trop Dis. 2012;6(12):e1966
pubmed: 23285306
Cell Death Differ. 2020 Dec;27(12):3209-3225
pubmed: 33037393
Lancet Infect Dis. 2020 May;20(5):536
pubmed: 32145189
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
PLoS Negl Trop Dis. 2020 Aug 14;14(8):e0008426
pubmed: 32797035
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Blood. 2013 Nov 14;122(20):3405-14
pubmed: 24009231
J Travel Med. 2020 Sep 26;27(6):
pubmed: 32657339
Am J Trop Med Hyg. 2020 Aug;103(2):570-571
pubmed: 32539912
PLoS Negl Trop Dis. 2011 Jan 04;5(1):e926
pubmed: 21245912
Brief Bioinform. 2021 May 31;:
pubmed: 34058750
Front Immunol. 2020 Jun 23;11:1518
pubmed: 32655582
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
BMC Bioinformatics. 2003 Jan 13;4:2
pubmed: 12525261
Biochim Biophys Acta. 2008 Dec;1780(12):1383-7
pubmed: 18708124
Mol Inform. 2019 Jul;38(7):e1900032
pubmed: 30957433
J Pers Med. 2020 Aug 05;10(3):
pubmed: 32764275
Science. 2015 May 8;348(6235):648-60
pubmed: 25954001
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
J Infect Dis. 2014 Jul 1;210(1):138-45
pubmed: 24446526
Aging (Albany NY). 2020 May 2;12(9):7639-7651
pubmed: 32364527
Nucleic Acids Res. 2020 Jul 2;48(W1):W307-W312
pubmed: 32313938
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Rev Soc Bras Med Trop. 2019 Nov 14;52:e20180353
pubmed: 31778418
Nat Neurosci. 2020 Aug;23(8):939-951
pubmed: 32690969
Front Microbiol. 2014 Jun 17;5:296
pubmed: 24987391
Cell Syst. 2021 Jan 20;12(1):23-40.e7
pubmed: 33096026
PLoS Pathog. 2020 Aug 10;16(8):e1008754
pubmed: 32776975
Cell Res. 2020 Dec;30(12):1078-1087
pubmed: 33159154
J Infect Dis. 1998 Mar;177(3):778-82
pubmed: 9498463